Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Normolyt is an oral rehydration solution (ORS) provided as a granulate for dissolution in water, primarily used to treat dehydration resulting from acute gastroenteritis, particularly in children. The product contains a balanced mixture of anhydrous glucose, sodium chloride, potassium chloride, and sodium citrate. Its mechanism of action relies on the sodium-glucose cotransporter 1 (SGLT1) in the intestinal mucosa; the presence of glucose facilitates the active transport of sodium, which in turn drives the osmotic absorption of water. Normolyt is marketed in several European countries, including Austria, Hungary, and the Czech Republic, and has been the subject of Phase 4 clinical studies evaluating its acceptance and metabolic effects compared to other rehydration solutions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Normolyt.